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Abstract 
Background: This study aims to assess Plakophilin-3 (PKP3) as a surrogate biomarker of circulating tumor cells in 
patients with gastrointestinal cancer.  
Methods: The primary aim is to estimate the diagnostic accuracy of PKP3 real-time reverse transcriptase-PCR in 
blood. Receiver operating characteristic curves were constructed. Correlations between the blood PKP3 levels and 
the clinicopathologic features of the study subjects were analyzed. Logistic regression was used to predict outcomes 
based on PKP3.  
Results: Sixty-four patients with gastrointestinal cancer and 23 controls were included. The mean relative PKP3 
mRNA expression was 48.45 in cancer patients and 2.8 in controls (P < 0.0001). Comparing the PKP3 levels in 
patients and controls, the area under the curve was 0.852 (95% confidence interval, 0.76-0.94; P < 0.0001) in receiver 
operating characteristic analysis. A higher blood level of PKP3 mRNA was associated with a more advanced stage (P 
= 0.025), pT3-4 tumors (P = 0.028), metastasis (P = 0.021), and residual (R2) disease (P = 0.037). Higher PKP3 
mRNA was associated with the risk of cancer progression and death (odds ratio, 3.875; 95% confidence interval, 
1.781-8.430; P = 0.001).  
Conclusions: Increased PKP3 mRNA was detected in the blood of gastrointestinal cancer patients. Significant 
correlations were found with advanced stage, pT3-4, metastatic disease, and the residual disease status. PKP3 mRNA 
in blood was associated with the risk of cancer progression and death.  
Impact: PKP3 mRNA can be used as a marker of subclinical disease in gastrointestinal cancer and thus holds 
potential clinical relevance as a predictor for disease outcome. Cancer Epidemiol Biomarkers Prev; 19(6); 1432–40. 
Introduction 
Cancers of the gastrointestinal tract are among the most frequent causes of cancer death worldwide (1). 
The stage at diagnosis and the available options for curative surgery remain the most important prognostic 
factors. However, distant and locoregional relapses frequently occur despite resection and adjuvant 
therapy. Circulating tumor cells (CTC) and occult metastasis (i.e., micrometastasis) are considered early 
events in the multistep process of metastasis (2). Detection of tumor cells in the blood or minimal 
deposits in distant organs such as the bone marrow and in peritoneal cavity could be important to identify 
patients at a high risk of disease progression. Sensitive methods for CTC detection could be used as 
surrogate markers for adjuvant treatment in gastrointestinal cancer patients. Furthermore, characterization 
of the molecular signature of CTC may help in the selection of new therapeutic targets and in the 
determination of which patients are suitable for these treatments (3, 4).  
Immunologic and molecular approaches are the major methods used to detect isolated tumor cells. 
PCR amplification of tissue or tumor-specific mRNA is the most powerful tool for the detection of 
circulating or occult metastatic cells (5). Cytokeratins 19 and 20, CEA, guanylyl cyclase C, hTERT, Ep-
CAM, and EGFR are among the mRNA markers used in different reverse transcriptase-PCR (RT-PCR) 
assays in gastrointestinal cancer patients (6-8). However, genetic heterogeneity even at the single-cell 
level (9, 10), downregulation of mRNA marker in tumor cells, or low-level transcription of the selected 
target in the hematopoietic compartment could compromise both the sensitivity and the specificity of 
molecular methods (11-13). The selection of novel gastrointestinal cancer–specific transcripts and the 
development of quantitative RT-PCR assays remain outstanding research questions (14, 15).  
Our study aims to identify novel gastrointestinal cancer–specific mRNA markers for detection of CTC 
in the blood. The development of mRNA biomarker assay for CTC detection was conducted following 
the proposed guidelines of the Early Detection Research Network from the National Cancer Institute (16). 
The phase I preclinical study was done by means of bioinformatics tools to obtain a quantitative, 
comprehensive, and unbiased profile of gene expression of colorectal, gastric, and pancreatic 
adenocarcinoma. These in silico data were used to identify and prioritize molecular markers that are 
highly expressed in gastrointestinal cancers but absent in hematopoietic-derived libraries. Selected genes, 
including plakophilin-3 (PKP3), were evaluated in cell lines and clinical specimens. Finally, a 
quantitative RT-PCR (qRT-PCR) assay for PKP3 was developed to identify blood-borne cells in cancer 
patients (17).  
PKP3 is a member of the p120ctn/plakophilin subfamily of β-catenin (CTNNB1) and armadillo (ARM) 
proteins. PKP3 is present in the desmosomes of epithelial cells and binds desmogleins, desmocollin, 
plakoglobin, desmoplakin, and keratin 18. PKP3 is involved in desmosome-dependent cell adhesion and 
is specific to epithelial cells. It also functions in signal transduction (18-21). Little is known about the 
possible biological role of PKPs in tumor invasion and metastasis (22). In addition, knowledge of the 
regulation of their expression is limited. Recent studies have shown evidence that the PKP3 protein in 
tumor may serve as a useful marker for predicting the clinical outcome of head and neck (23) and non–
small cell lung (24) cancers. An oncogenic role for PKP3 in non–small cell lung cancer has been 
suggested, as PKP3 promotes growth and invasion in experimental models (24). Other investigators (25) 
have shown that this protein is highly expressed in various types of adenocarcinomas, including 
colorectal, pancreatic, and prostate tumors. Recently, PKP1, another member of plakophilins, has been 
described as a marker for subclinical disease in blood and bone marrow in the Ewing family of tumors 
(26).  
To assess PKP3 as a new surrogate biomarker of CTC, we examined PKP3 mRNA in the blood of 
gastrointestinal cancer patients using qRT-PCR. Our findings indicate that quantitative assessment of 
PKP3 mRNA can be a marker of subclinical disease in gastrointestinal cancer patients and has potential 
clinical relevance as a predictor of disease outcome.  
Materials and Methods 
Patients 
Consecutive patients with gastrointestinal cancer from the Medical Oncology Unit at University Hospital 
in La Coruña (Spain) were included in the study. Inclusion criteria were as follows: patients with a 
confirmed pathologic diagnosis of invasive adenocarcinoma of the gastrointestinal tract, including 
colorectal, gastric, and pancreatic tumors; stage I-III patients with no prior systemic therapy for 
gastrointestinal cancer; stage IV patients without previous systemic therapy or with confirmed cancer 
progression after such treatment; and patients providing written informed consent. Exclusion criteria were 
defined as follows: patients with any other previous malignancy; patients with coagulation disorders; 
patients with platelet count less than 20 × 109 per liter; and patients with any previous systemic therapy 
for cancer except stage IV patients with progressive disease confirmed at the time of blood sampling.  
The diagnostic work-up included a clinical examination, blood sampling with CA 19.9 and 
carcinoembryonic antigen (CEA) serum determination, an endoscopy (when clinically indicated), a chest 
X-ray, and computed tomography scanning of the abdomen and pelvis. A chest computed tomography 
was done on the upper digestive tract and on rectal tumors and stage IV patients. Patients were followed 
to observe disease progression with imaging every 6 to 12 weeks.  
Serum CEA (with an upper limit of normal of 5 ng/mL) and CA 19.9 (with an upper limit of normal 
of 37 units/mL) levels were determined using enzyme immunoassay test kits (Advia Centaur, Siemens 
Healthcare Diagnostics), according to the manufacturer's instructions.  
Blood samples for qRT-PCR analysis were obtained after surgery, before neoadjuvant chemotherapy, 
or in the presence of active, clinically and radiologically advanced progressive disease. At least the first 5 
mL of blood obtained was discarded to avoid contamination with epidermal cells.  
Controls were recruited from the patient families. We only excluded those with a previous history of 
malignant disease. Thus, controls with different chronic but stable disease (i.e., hypertension, diabetes 
mellitus, or heart disease, among others) were eligible and consecutively recruited. Controls were selected 
to include a sex and age distribution comparable to the patient group.  
This study was approved by the institutional review board of the Ethic Committee of Clinical 
Investigation of Galicia (Spain), and written informed consent was obtained from all patients and 
controls.   
Pathologic analysis 
Primary tumors and regional lymph nodes collected during surgery were processed on a routine 
diagnostic basis. Histologic tumor type, depth of tumor invasion, and nodal involvement were analyzed, 
and the disease was staged and graded according to the tumor-node-metastasis system (27). Residual 
disease status at the time of blood sampling was classified as R0 when no residual disease was present 
after surgery, R1 when microscopic residual disease was found, and R2 in the presence of macroscopic 
disease. Patients from whom blood was obtained before the start of neoadjuvant systemic treatment were 
categorized as R2.  
Processing of blood samples and mRNA isolation 
Peripheral venous bloods (10 mL) were collected in EDTA-containing tubes. Samples were stabilized 
within 1 hour after withdrawal in guanidinium-based RNA/DNA stabilization reagent for blood and bone 
marrow (Roche) at 10% (v/v) without cell and plasma separation. Isolation reagent for blood and bone 
marrow (Roche) was used for mRNA extraction according to the manufacturer's protocol with minor 
modifications (17). Purified poly(A)+ RNA was further processed in qRT-PCR or stored at −80°C until 
use. The RNA concentration was determined by UV absorption at 260 nm. The A260/A280 ratio was 
calculated to assess RNA quality and purity. In addition, RNA integrity was confirmed by 2% agarose gel 
electrophoresis and ethidium bromide staining.  
Reverse transcription and quantitative real-time PCR 
Reverse transcription was done on 0.02 μg of mRNA using the SuperScript First-Strand Synthesis System 
for RT-PCR (Invitrogen) as described previously (17). Real-time PCR analysis was done with the primers 
and conditions previously described (17) using a LightCycler 480 (Roche) and SYBR Green I Master 
(Roche).  
The PCR reaction consisted of 10 μL of Master Mix 2× concentration, 1.4 μL of forward (PKP3 2F) 
and reverse (PKP3 1R) primers at 5 μmol/L, 4 μL of cDNA, and PCR-grade water up to a final volume of 
20 μL in each well in a LightCycler 480 Multiwell Plate 96.  
The maximum number of cycles was 50. If no fluorescent signal was detected on the amplification 
plots after 40 cycles, the marker mRNA was assumed to be absent from the blood samples.  
Hypoxanthine-guanine phosphoribosyl-transferase 1 (HPRT1) was selected as a housekeeping gene 
using the human endogenous control gene panel (TATAA Biocenter) as previously reported (17). HPRT1 
amplification served as an internal control and was used to verify the integrity of the RNA and the 
efficacy of reverse transcription. Any specimen with inadequate HPRT1 mRNA was excluded from the 
study.  
We verified the specificity of PCR by melting curve analysis. Data analysis was done with Light 
Cycler 480 Relative Quantification software (Roche). Relative levels of expression were calculated by the 
2−ΔΔCt method (28). Each assay was done at least in triplicate. The average value of the replicates was 
used as quantitative value for each sample. Each assay included marker-positive, marker-negative, and 
reagent with no template controls.  
PKP3 expression in colorectal cancer  
Eleven pairs of primary colon carcinoma tissues and matched normal colonic mucosa were obtained from 
patients undergoing surgery and were frozen and stored at −80°C until the extraction of RNA. We 
microscopically confirmed that the tumor specimens were predominantly (>80%) cancer tissue. RNA 
isolation was done using the mirVana isolation kit (Applied Biosystems), according to the manufacturer's 
instructions. cDNA synthesis was done with 1 μg of total RNA using a SuperScript First-Strand Synthesis 
kit as described (17). PKP3 mRNA was quantified using SYBR-Green qRT-PCR and normalized using 
the 2−ΔΔCt method relative to HPRT1 as previously described. All PCRs were done in triplicate.   
Study design and statistical analysis methods 
This project was designed as a prospective early-phase, diagnostic case-control study. The primary aim is 
to estimate the diagnostic accuracy and usefulness of PKP3 as measured by qRT-PCR in blood as a 
clinical biomarker (16). Receiver operating characteristic (ROC) curves were constructed by plotting 
sensitivity (Y axis) versus 1−specificity (X axis), and the areas under the curves (AUC) were calculated. 
Secondary aims include the evaluation of PKP3 mRNA blood levels in gastrointestinal cancer patients 
and the disease characteristics of these patients. Non normality of the distribution of PKP3 values was 
confirmed by Kolmogorov-Smirnov test. Thus, nonparametric tests (Mann-Whitney and Kruskal-Wallis 
tests) were used to analyze the potential association between PKP3 expression and the clinical and 
pathologic features of the study subjects.  
Progression-free survival (PFS) was measured as the time between the baseline blood sampling for 
PKP3 analysis and the documentation of first tumor progression based on clinical and radiological studies 
or death. Patients who were alive and progression-free at the time of analysis were censored by using the 
time between the baseline PKP3 assessment and their most recent follow-up evaluations. Kaplan-Meier 
methodology was used to estimate median PFS.  
Logistic regression analyses were used to assess the effect of PKP3 mRNA levels on the risk of 
disease progression or death. Patients were classified according to their PFS status at 2 years into two 
groups: disease progression or death and alive without disease progression. Univariate and multivariate 
analyses were done. Odds ratios (OR) and 95% confidence intervals (95% CI) were estimated.  
For all analyses, a P value of less than 0.05 was considered statistically significant. SPSS Software 
(version 16.0) was used for the analysis.  
The study design and results are presented in accordance with the REMARK guidelines (29).  
Results 
Patients and clinical data 
From July 2004 to July 2006, 64 consecutive patients with histologically proven gastrointestinal cancer 
and 23 matched controls were recruited for this study. The clinical characteristics of the cancer subjects 
are shown in Table 1.  
Blood was obtained after R0 or R1 surgery in 17 patients. In 47 patients, blood samples were obtained 
before neoadjuvant chemotherapy or in the presence of active metastatic disease, both of which were 
categorized as R2 at the time of blood sampling.  
All patients were followed up until death or the end of the study. Tumor progression was detected in 
52 patients (81.2%). The median PFS was 37.7 weeks (95% CI, 28.2-47.2). Forty-six patients (71.9%) 
died of advanced disease. Fifty PFS events had occurred at 2 years of follow-up. The mean follow-up 
time for the patients still alive at the time of the analysis was 192.2 ± 41.2 weeks (median, 204.6 weeks; 
range, 124.3-239.4 weeks).  
 
  
Table 1. Patients and clinicopathologic data 
   
Age (y)   
Median (SD) 62.3 (10.1)  
Range 31-80  
 N % 
<65 36 56 
≥65 28 44 
Gender   
Female 22 34 
Male 42 66 
Primary tumor site   
Colon and rectum 48 74 
Stomach 8 12.5 
Pancreas 8 12.5 
Stage   
I-II 5 7.8 
III 14 21.9 
IV 45 70.3 
pT   
pT1-pT2 8 14.1 
pT3 37 64.9 
pT4 12 21.1 
pTx 7 9.9 
pN   
pN0 10 15.6 
pN1 29 45.3 
pN2 11 17.2 
pNx 14 21.9 
M   
M0 20 31.2 
M1 44 68.8 
R status   
R0-R1 17 26.6 
R2 47 73.4 
No. of metastatic sites   
0 20 31.2 
1 32 50 
≥2 12 18.8 
Location of metastasis   
None 20 31.2 
Liver only 26 40.6 
Liver and other 12 18.8 
Nonliver metastasis 6 9.4 
Grade   
1 10 15.6 
2 44 68.8 
3 10 15.6 
Vascular/perineural invasion   
Unknown 16 25 
No 22 34.4 
Yes 26 40.6 
   
 
Expression of PKP3 mRNA transcripts in blood samples  
Real-time quantitative assessment of PKP3 mRNA was done using 87 blood samples (64 patients and 23 
controls). PKP3 transcripts were detected in the blood of 93.8% (60 of 64) of patients but only in 39.1% 
(9 of 23) of controls (P < 0.0001; Fisher's exact test). The mean relative PKP3 mRNA expression was 
48.45 (95% CI, 29.61-67.29) in cancer patients and 2.8 (95% CI, 0.14-5.48) in controls (P < 0.0001, U-
Mann-Whitney test).  
ROC curves were constructed by plotting sensitivity versus 1−specificity. Comparing the relative 
PKP3 levels in patients and controls, the AUC was 0.852 (95% CI, 0.76-0.94; P < 0.0001). Although the 
values of the AUCs were lower, statistically significant results were obtained when analyzing PKP3 
levels in controls compared with stage I-III patients (AUC, 0.769; 95% CI, 0.623-0.915; P = 0.003) and 
stage I-III patients compared with stage IV patients (AUC: 0.678; 95% CI, 0.526-0.829; P = 0.026; Fig. 
1).  
 
 
 
Figure 1. ROC curves were constructed by plotting sensitivity versus 1−specificity. PKP3 mRNA relative levels were quantified in 
blood obtained from patients with gastrointestinal cancer (n = 64) and from controls (n = 23). Curves are shown comparing controls 
versus cancer patients (A), controls versus stage I-III patients (B), and stage I-III patients versus stage IV patients (C). AUCs, 95% 
CIs, and P values are shown.  
In addition, ROC curves were analyzed, comparing the PKP3 levels in blood in each subgroup of 
patients (colorectal, gastric, and pancreatic cancer) with the PKP3 levels in the control group. Statistically 
significant results were obtained in each pair-wise analysis, and the AUCs were 0.875 (95% CI, 0.789-
0.965; P < 0.001) for colorectal cancer, 0.821 (95% CI, 0.635-1; P = 0.008) for gastric cancer, and 0.745 
(95% CI, 0.570-0.963; P = 0.042) for pancreatic cancer.  
Different cutoff strategies were used to estimate PKP3 levels as a surrogate for discrimination 
between the presence and absence of CTC in blood samples from gastrointestinal cancer patients (Table 
2). Considering the 95% CI for the mean relative levels in healthy or benign donors, we set the PKP3 
cutoff at 5.5. PKP3 counts higher than 5.5 were found in 60.9% of cancer patients. The specificity was 
82.6%. Using values obtained in the ROC curve analysis, PKP3 levels higher than 15.25 were observed in 
53.1% of the cancer patients; the specificity was 95.7%.   
Table 2. Diagnostic performance of PKP3 mRNA qRT-PCR  
 
Sensitivity (%; 
95% CI) 
Specificity (%; 
95% CI) 
Positive predictive value 
(%; 95% CI) 
Negative predictive value 
(%; 95% CI) 
Accuracy (%; 95% CI) 
Patients and controls 
PKP3 >5.5 60.9 (47.9-72.6) 82.6 (60.5-94.3) 90.7 (76.9-96.9) 43.2 (28.7-58.9) 66.7 (55.7-76.2) 
PKP3 >15.25 53.1 (40.3-65.6) 95.7 (40.3-65.6) 97.1 (83.4-99.9) 42.3 (29.0-56.7) 64.4 (53.3-74.1) 
Stage I-III and stage IV patients 
PKP3 >5.5 66.67 (50,9-79,6) 52.6 (29.5-74.8) 76.92 (60.3-88.3) 40.0 (21.8-61.1) 62.5 (49.5-74.0) 
PKP3 >15.25 57.8 (42.2-72.0) 57.9 (33.9-78.9) 76.5 (58.4-88-6) 36.7 (20.5-56.1) 57.81 (44.9-69.8) 
      
 
Clinical significance of PKP3 mRNA in blood  
The clinical and pathologic characteristics and the PKP3 mRNA expression in blood from cancer patients 
are shown in Table 3. A higher relative level of blood expression of PKP3 was associated with a more 
advanced stage (P = 0.025), pT3-4 (P = 0.028), metastatic disease (P = 0.021), and residual disease (R2) 
status (P = 0.037).  
The relative expression of PKP3 mRNA in the blood was higher in patients with colorectal (mean, 
51.5) and pancreatic (mean, 53.3) cancer than in gastric cancer (mean, 25.4) patients, although these 
differences were not significant (Kruskal-Wallis test, P = 0.702).  
In pair-wise comparisons of the mean relative PKP3 mRNA expression in blood in each subgroup of 
patients (colorectal, gastric, and pancreatic cancer) with the expression in control group, the relative 
expression of PKP3 in each cancer subgroup was higher than in controls (U-Mann-Whitney test; P = 
0.0001, P = 0.006, and P = 0.043 for colorectal, gastric, and pancreatic cancer, respectively).  
CEA and CA 19.9 serum levels were increased above the upper limits of normal in 46.8% and 41.3% 
of the patients, respectively. There were no correlations between PKP3 mRNA levels and either CEA or 
CA 19.9 in serum (Spearman's ρ coefficients = 0.144 and 0.010, respectively).  
To explore the possible influence of recent surgery on the circulation of tumor cells, we analyzed 
PKP3 levels according to the time interval from operation and blood sampling (Table 4). The mean time 
from surgery to blood sampling for PKP3 mRNA quantification was 354.3 ± 396.3 days (median, 126.5 
days; range, 30-1,392 days). The 25th percentile was 48 days. There was no significant difference in 
PKP3 levels between time intervals (<48 or ≥48 days) from the last surgery.  
  
Table 3. Distribution of clinicopathologic parameters and levels of PKP3 mRNA in the blood  
Parameter n PKP3 (mean)  SEM P 
     
Age (y)    0.656 
<65 35 52.3 16.2  
≥65 29 40.4 13.5  
Gender    0.354 
Male 42 47 9.6  
Female 22 51.2 20.9  
Primary tumor site    0.702* 
Colon and rectum 48 51.5 11.6  
Stomach 8 25.4 10.6  
Pancreas 8 53.3 27.2  
Stage    0.025 
I-III 19 44.6 25.9  
IV 45 48.5 10.5  
pT    0.028 
pT1-T2 8 29.4 27.4  
pT3-T4 49 50 11.9  
pN    0.128 
Node negative 10 66.7 21.5  
Node positive 42 42.6 12.5  
M    0.021 
M0 20 38.2 22.2  
M1 44 53.1 9.4  
R status    0.037 
R0-R1 17 21.6 7.8  
R2 47 58.2 12.3  
No. of metastatic sites    0.053* 
0 20 38.2 22.2  
1 32 52.2 11.4  
≥2 12 55.7 17.3  
Location of metastasis    0.069 
None 20 38.2 22.2  
Liver 38 54 10.7  
Nonliver metastasis 6 47.5 15.8  
Grade    0.383* 
1 10 32.5 20.5  
2 44 56.2 12.6  
3 10 30.5 11.7  
Vascular/perineural invasion    0.808 
No 23 53.9 20.1  
Yes 27 41.5 11.2  
     
 
NOTE: PKP3 mRNA relative expression levels are shown as arbitrary units. Mann-Whitney Test 
or *Kruskal-Wallis Test were used. P values of less than 0.05 are italicized. 
Table 4. PKP3 levels according to time interval between surgery and blood sampling  
 n PKP3 median (SD)  P* 
    
Patients with previous surgery 50 39.56 (55.96)  
Time from surgery to blood sampling <48 d 11 46.29 (67.01) 0.897 
Time from surgery to blood sampling ≥48 d 39 37.65 (53.29)  
    
 
↵*Two-sided Mann-Whitney test. 
  
Logistic regression was used to predict PFS event at 2 years based on PKP3 mRNA levels in the 
blood of cancer patients (Table 5). In univariate analysis, using a PKP3 cutoff value of 5.5 as previously 
defined, higher PKP3 levels were associated with a higher risk of cancer progression or death (OR, 3.875; 
95% CI, 1.781-8.430; P = 0.001). 
Table 5. Logistic regression model for predictive factors associated with PFS events 
Variable Subset Univariate  Multivariate 
  OR (95% CI) P  OR (95% CI) P 
       
PKP3 mRNA  ≤5.5/>5.5 3.875 (1.781-8.430) 0.001  0.898 (0.104-7.777) 0.922 
Residual disease R0-1/R2 2.898 (1.823-4.608) <0.0001  1.797 (0.414-7.798) 0.434 
Stage I-II-III/IV 2.699 (1.791-4.067) <0.0001  17.32 (1.150-260.8) 0.039 
Vascular/perineural invasion No/yes 5.75 (1.989-16.626) 0.001  14.885 (1.256-176.4) 0.032 
Lymph node Negative/positive 2.818 (1.417-5.607) 0.003  0.223 (0.018-2.775) 0.244 
Invasion depth (pT) pT1-2/pT3-4 1.901 (1.365-2.646) <0.0001  0.317 (0.034-2.946) 0.313 
Age <65 y/≥65 y 2.500 (1.201-5.205) 0.014  0.093 (0.008-1.026) 0.053 
       
 
Considering PKP3 mRNA levels as a continuous variable (30) in the logistic regression analysis, 
increasing levels were associated with the risk of cancer progression or death (OR, 1.011; 95% CI, 1.001-
1.020; P = 0.025).  
Using multivariate logistic regression analysis, only stage IV (OR, 17.32; 95% CI, 1.150-260.8; P = 
0.039) and vascular/perineural invasion (OR, 14.885; 95% CI, 1.256-176.4; P = 0.032) remained 
significant for PFS events.  
PKP3 is overexpressed in colorectal carcinomas  
PKP3 mRNA content was determined in 11 pairs of frozen colorectal tumors and matched normal colon 
epithelia using real-time qRT-PCR. The PKP3 mRNA levels were significantly higher in cancer tissue 
than in normal colonic mucosa (P = 0.001). Ten cancer samples (90.9%) overexpressed PKP3 in 
comparison with the normal tissues (mean fold increase, 3.47 ± 2.25).  
Discussion 
PCR amplification of tissue- or tumor-specific mRNA is a powerful analytic tool for surrogate detection 
of CTC. Real-time RT-PCR allows for quantification of the cancer cell load in the peripheral blood, and, 
theoretically, the determination of cutoff values indicating mRNA expression levels of clinical relevance 
in cancer patients. However, several limitations of this approach have been described. Both sensitivity 
and specificity are dependent on the expression level of markers in tumor cells as well as their 
background expression in the blood. Thus, the identification of appropriate target mRNA transcripts that 
are useful for clinical detection of CTC in the blood remains clearly a remarkable issue.  
In a previous study (17), we used DDD (Digital Differential Display) to search SAGE (Serial Analysis 
of Gene Expression) and EST (Expressed Sequence Tags) libraries of the Cancer Genome Anatomy 
Project, and we constructed a gene expression profile of colorectal, gastric, and pancreatic cancers in 
comparison with the hematopoietic gene profile. PKP3 was selected, taking into account its upregulation 
in gastrointestinal cancer and its low-level expression in the hematopoietic compartment. In addition, the 
diagnostic performance of the PKP3 mRNA assay was better when comparing with the results obtained 
with an EGFR mRNA assay in the same blood sample cohort based on the ROC curve analysis (17).  
Building on our phase I preclinical study, the current study was intended to assess the diagnostic 
performance of quantitative RT-PCR detection of mRNA PKP3 in the blood of patients with different 
gastrointestinal cancers, including colorectal, pancreatic, and gastric adenocarcinomas. Patients were 
included to accurately reflect everyday clinical practice. Our results showed that blood mRNA PKP3 
levels were significantly correlated with different pathologic and clinical prognostic factors in 
gastrointestinal cancer, including stage, depth of tumor invasion, presence of metastases, and residual 
disease status.  
The sensitive quantification of PKP3 and the definition of cutoff values improved the specificity of 
our assay. Different cutoff strategies were used to discriminate between the presence and absence of CTC 
in blood samples from gastrointestinal cancer patients. Threshold levels estimated with the ROC curves 
were associated with the risk of relevant clinical end point as PFS events by logistic regression analysis. 
Furthermore, the PKP3 mRNA levels, which were analyzed as a continuous variable, were associated 
with the risk of cancer progression and death.  
Previous studies have shown that molecular markers for CTC in gastrointestinal cancer patients are 
increasingly detected when blood is obtained perioperatively or intraoperatively (31-33). However, the 
prognostic impact of this tumor cell shedding during surgery has yet to be shown. In our study, blood 
samples were obtained several weeks after surgery if an operation was done. To explore the possible 
influence of recent surgery on the circulation of tumor cells, PKP3 levels were analyzed according to time 
interval between surgery and blood sampling; however, no significant differences in PKP3 levels between 
time intervals were found. Thus, we hypothesized that only circulating and viable cancer cells resistant to 
anoikis were detected using the mRNA PKP3 assay.  
In a previous study, Furukawa et al. (24) had shown that overexpression of PKP3 in non–small cell 
cancer cell lines promotes cell motility and invasion by association with dynamin 1–like protein. 
Moreover, cancer cells mainly exhibited a cytoplasmic distribution of overexpressed PKP3 protein, 
consistent with the results of a previous report (23). Semiquantitative RT-PCR analysis had revealed (24) 
that there was no significant correlation of gene expression between PKP3 and PKP3-associated 
desmosomal components in lung cancer samples and stable transfected cells.  
For epithelial malignancies, the epithelial-mesenchymal transition (EMT) is considered one of the 
crucial events in the metastatic process (2, 34). EMT involves the disruption of epithelial cell homeostasis 
and the acquisition of a migratory mesenchymal phenotype, allowing these cells to invade and circulate in 
the blood to the site of metastasis development. Interestingly, Aigner et al. (35) have shown that the 
transcriptional deregulation of PKP3 by the E-cadherin repressor ZEB1 contributes to disintegration of 
intercellular adhesion and to the EMT. At the invasive front of tumors, where EMT and releasing of 
CTCs take place, ZEB1 is upregulated and thus PKP3 protein associated with desmosomes are 
downregulated (24, 35), promoting desmosome instability and increased cell migration. However, the 
cancer cells still display a PKP3 cytoplasmic pool (35). This cytoplasmic pool may be in relation with 
additional functions for PKP3 in cells, beyond its participation in desmosomes. During environmental 
stress conditions, like those occurring during cancer progression, PKP3 is found associated with other 
proteins in “stress granules” containing stalled translation initiation complexes (36). This indicates that 
PKP3 is involved in RNA metabolism, protein translation, and stress response (36). These findings could 
explain the PKP3 expression in CTCs after undergoing EMT. An alternative or complementary 
explanation is that CTCs preserve epithelial components, like PKP3, waiting for reversing their 
mesenchymal status through mesenchymal-to-epithelial transition and generate metastasis foci. In line 
with this, the majority of CTCs isolated in breast cancer patients by the presence of epithelial surface 
markers (Ep-CAM) also show coexpression of EMT and stem cell markers (37). In addition, we have 
detected PKP3 mRNA expression also in colorectal cancer metastasis (17).  
The limitations of this study must be considered. Patients with adenocarcinomas from different 
primary digestive sites (including colorectal, gastric, and pancreatic tumors) were included, which may 
influence the clinical relevance of PKP3 quantification to any one group. However, our results suggest 
that PKP3 can be considered an epithelial-selective marker and not an organ-specific marker. 
Bioinformatics analysis has shown high expression levels in different normal epithelia and tumors, 
including gastric, colorectal, and pancreatic carcinomas (17). Using real-time quantitative PCR, we 
showed that PKP3 mRNA was overexpressed in colorectal tumors in comparison with matched normal 
colonic tissues. Although the inclusion of patients with different stages of disease and residual tumor 
situations could be considered an additional limitation of this study, we suggest that this pragmatic design 
accurately reflects the patients attending everyday in the oncology clinic. Thus, the diagnostic 
performance of PKP3 mRNA quantification has been estimated in a cohort of patients truly representative 
of those found in the clinical setting. However, to adequately assess the prognostic role, if any, of PKP3 
mRNA levels in the blood, a larger, more homogeneous cohort of patients is clearly needed.  
In conclusion, our findings indicate that the quantitative assessment of PKP3 mRNA in blood can be 
used as a marker of subclinical disease and, thus, holds potential clinical relevance as a predictor for 
disease outcome.  
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